GVAG
SLS icon

Great Valley Advisor Group’s SELLAS Life Sciences SLS Stock Holding History

Great Valley Advisor Group’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$16K – 981
2025
Q3 		$16K Sell
10,000
-10,000
-50% -$17.8K ﹤0.01% 920
2025
Q2 		$44K Buy
+20,000
New +$30.7K ﹤0.01% 887

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Great Valley Advisor Group's SLS Position: Q4 2025 in Review

Great Valley Advisor Group sold out of SELLAS Life Sciences (SLS) in Q4 2025, closing a stake of 10,000 shares — an estimated $16K sold.

Great Valley Advisor Group first reported a position in SLS in Q2 2025 and held it in 2 quarters. The position peaked at $44K in Q2 2025. 112 funds tracked by Wall St. Rank hold SLS as of Q4 2025.

  • Great Valley Advisor Group reported no remaining SELLAS Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Great Valley Advisor Group sold 10,000 SELLAS Life Sciences shares in Q4 2025, an estimated $16K.
  • Great Valley Advisor Group first reported a position in SELLAS Life Sciences in Q2 2025 and held it in 2 quarters.
  • Great Valley Advisor Group's SELLAS Life Sciences position peaked at $44K in Q2 2025.
  • 112 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2025.

Based on Great Valley Advisor Group's 13F filing for Q4 2025, filed 12 Feb 2026.